bumetanide + furosemide

Bumetanide and furosemide are both loop diuretics that work by inhibiting sodium-potassium-chloride cotransporters (NKCC2) in the ascending limb of the loop of Henle in the kidneys. They prevent the reabsorption of sodium, chloride, and water, leading to increased excretion and diuresis. While they share a similar mechanism of action, they differ in potency, bioavailability, and metabolism. Bumetanide is approximately 40 times more potent than furosemide, with 1mg of bumetanide being equivalent to 40mg of oral furosemide. Bumetanide has greater bioavailability (approximately 80%) compared to furosemide (approximately 50%), with less variability between patients. Bumetanide is metabolized by cytochrome P450 pathways, while furosemide undergoes glucuronidation. Both drugs are used to treat edema associated with congestive heart failure, hepatic disease, and renal disease including nephrotic syndrome.